Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct-acting antivirals

IF 3.4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Research Pub Date : 2025-01-22 DOI:10.1111/hepr.14162

Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi

{"title":"Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct-acting antivirals","authors":"Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi","doi":"10.1111/hepr.14162","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To clarify whether direct-acting antiviral treatment improves serum myostatin levels of patients with cirrhosis caused by hepatitis C virus.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 99 patients with type C liver cirrhosis were administered direct-acting antiviral treatment. The median age was 73 years, and 58 patients were women. We measured the levels of serum myostatin, decorin, follistatin, and insulin-like growth factor-1, as well as the skeletal muscle mass index at baseline. We measured the sustained virological response at 48 weeks.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Serum myostatin levels of the Child–Pugh class B or C group (<i>n</i> = 30) were significantly higher than those of the Child–Pugh class A group (<i>n</i> = 69) at baseline. The multivariate analysis indicated that the total bilirubin level and Mac-2 binding protein glycosylation isomer level were independent factors associated with serum myostatin levels. Serum myostatin levels significantly decreased, whereas the skeletal muscle mass index and insulin-like growth factor-1 level were significantly increased at 48 weeks.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Direct-acting antiviral treatment decreased serum myostatin levels and may improve sarcopenia in patients with cirrhosis.</p>\n </section>\n </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"631-637"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14162","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14162","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To clarify whether direct-acting antiviral treatment improves serum myostatin levels of patients with cirrhosis caused by hepatitis C virus.

Methods

A total of 99 patients with type C liver cirrhosis were administered direct-acting antiviral treatment. The median age was 73 years, and 58 patients were women. We measured the levels of serum myostatin, decorin, follistatin, and insulin-like growth factor-1, as well as the skeletal muscle mass index at baseline. We measured the sustained virological response at 48 weeks.

Results

Serum myostatin levels of the Child–Pugh class B or C group (n = 30) were significantly higher than those of the Child–Pugh class A group (n = 69) at baseline. The multivariate analysis indicated that the total bilirubin level and Mac-2 binding protein glycosylation isomer level were independent factors associated with serum myostatin levels. Serum myostatin levels significantly decreased, whereas the skeletal muscle mass index and insulin-like growth factor-1 level were significantly increased at 48 weeks.

Conclusions

Direct-acting antiviral treatment decreased serum myostatin levels and may improve sarcopenia in patients with cirrhosis.

Abstract Image

查看原文本刊更多论文

直接抗病毒药物治疗C型肝硬化患者血清肌生成抑制素水平的变化

目的探讨直接抗病毒治疗是否能改善丙型肝炎肝硬化患者血清肌生长抑制素水平。方法对99例丙型肝硬化患者进行直接抗病毒治疗。中位年龄为73岁，其中58例为女性。我们测量了基线时血清肌生长抑制素、decorin、卵泡抑制素和胰岛素样生长因子-1的水平，以及骨骼肌质量指数。我们在48周时测量了持续的病毒学反应。结果Child-Pugh B、C组（n = 30）血清肌生成抑制素水平显著高于Child-Pugh A组（n = 69）。多因素分析表明，总胆红素水平和Mac-2结合蛋白糖基化异构体水平是影响血清肌生长抑制素水平的独立因素。血清肌生长抑制素水平显著降低，而骨骼肌质量指数和胰岛素样生长因子-1水平在48周时显著升高。结论直接抗病毒治疗可降低肝硬化患者血清肌生成抑制素水平，改善肌肉减少症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Research 医学-胃肠肝病学

CiteScore

8.30

自引率

14.30%

发文量

124

审稿时长

1 months

期刊介绍： Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.